Ten big challenges ahead by Mark Wainberg
SPEAKER PRESENTATION Open Access
Ten big challenges ahead
Mark Wainberg
From International Symposium HIV and Emerging Infectious Diseases 2014
Marseille, France. 21-23 May 2014
1. Can We Cure AIDS? This is an intense area of investi-
gation at the current time with much focus on the activa-
tion of latently infected cells within reservoirs by such
agents as histone deacetylase inhibitors. However, there is
concern about some of these approaches due to considera-
tions of possible long-term toxicities involving the activat-
ing agents as well as questions about whether it will be
possible to activate all latently infected cells or not.
2. Can We Provide High Quality HIV Drugs to All
People at Need Regardless of Ability to Pay? At present,
people living in developing countries often receive sub-
standard therapy, with drugs such as Raltegravir being
available only for second-line therapy. So, when will our
best new drug, ie Dolutegravir, become available in
resource-limited settings?
3. How Will We Pay? There is a real risk that world-
wide assistance programmes will run out of funds.
4. Will Treatment as Prevention Work in the Real
World? Hopefully, the answer to this question will be Yes,
but we have already seen that other prevention strategies
have experienced difficulties when employed outside the
context of a controlled clinical trial.
5. Will Drug Resistance Compromise All Prevention
Strategies? Perhaps it is too early for HIV drug resis-
tance virologists to retire. The answer to this question
will be key and only time will provide an answer.
6. When Will We Have a HIV Vaccine? There is a very
limited rate of success in the development of vaccines to
all forms of sexually transmitted disease, with the obvious
exception being Human papilloma virus. We should be
more honest about this.
7. Are Microbicides Still in the Game? Clearly, they
would probably never be as popular as PREP, if it worked,
or as Treatment as Prevention.
8. Do PrEP and Intermittent PrEP Have a Chance?
Certainly, these are strategies that should be effective
when used together with counselling.
9. What if HIV Failed to Develop Resistance to a New
Drug in First-Line Therapy? If this were ever to happen,
it would change our thinking on how to prevent HIV
transmission in a dramatic way. For example, the use of
such a drug should potentially eliminate future new HIV
transmissions. How significant is it that no-one who has
received Dolutegravir in first-line therapy has yet devel-
oped resistance against it or is this only a matter of time?
10. What is the Impact of Global Warming on Infectious
Diseases and Will Future Dengue Epidemics Surpass the
HIV Pandemic in Incidence, Morbidity, and Mortality?
The range of the mosquitos that transmit West Nile virus
has already expanded to significant extent. Can Dengue be
far behind?
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